Grifols pursues development of coronavirus treatment based on blood plasma
Grifols, a global biotherapeutics company with more than 2,000 employees in North Carolina, will produce and test a potential COVID-19 therapy derived from the blood plasma of patients who have recovered from the coronavirus infection.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed